Regenerative Medicine and Stem Cells Technologies

Seattle biotech company NanoSurface Biomedical, Inc., a leading provider of biomimetic cell-based assay platforms and services, announced today that it has acquired Silene Biotech, a Seattle biotechnology company focused on stem cell banking and services.

With new findings, scientists may be poised to break a long impasse in research on Huntingtons disease, a fatal hereditary disorder for which there is currently no treatment.

An international team of researchers has succeeded in making 13,200 edits to a single cell—and the cell survived. In their paper uploaded to the bioRxiv preprint server, the team describes the edits they made, how they did it and why.

A new study in STEM CELLS Translational Medicine indicates mesenchymal stem cells (MSCs) are a safe and innovative option to heal normal tissue following radiotherapy. Alain Chapel, Ph.D., and Annette Larsen, DVM, Ph.D., of the Institut National de la Santé et de la Recherche Médicale (INSERM) in France led the team that conducted this research.

Researchers from the University of Barcelona have shown that defective versions of human brain cells called astrocytes are linked to the buildup of a toxic protein that is the hallmark of Parkinsons disease.

Beauty might only be skin deep, but for those wondering how to keep that skin young, scientists may have found an answer in the form of a protein that encourages cell competition.

Mast cells are critically involved in immunity and immune disorders. However, they are rarely cultured ex vivo for experimental manipulation because of the difficulty in isolating useful numbers and limitations related to 2-D culture. A new study reports the successful development of authenticated mast cells by culturing hematopoietic stem cells in an engineered 3-D connective tissue matrix. The work is published in Tissue Engineering.

Scientists studying one of the most common forms of childhood cancer have made an important breakthrough in understanding how the disease progresses.

The nanotechnology platform, which uses special tiny rods for sensing, allows researchers to confirm the identity of human stem cell fates and their biomarkers, or biological molecules, without destroying them, according to a study in ACS Nano. Thats been a major issue during pre-clinical research on stem cells because it limits further analyses and biomedical applications.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the United Kingdom’s (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted authorization of the first-in-human clinical trial to evaluate a Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) therapy.